Home Healthcare Biotechnology Next-Generation Gynecological Cancer Diagnostics Market

Next-Generation Gynecological Cancer Diagnostics Market Size, Share & Trends Analysis Report By Technology (Next generation sequencing, Polymerase chain reaction (PCR), DNA Microarrays, Multiplexing, Protein Microarrays, Others), By Cancer Type (Breast, Lung, Colorectal, Prostate, Cervical, Others), By Function (Cancer Screening, Therapeutic Monitoring, Risk Analysis) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: July 24, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Next-Generation Gynecological Cancer Diagnostics Market, By Technology 2022-2034 (USD MILLION/ Units)
    1. Next generation sequencing
    2. Polymerase chain reaction (PCR)
    3. DNA Microarrays
    4. Multiplexing
    5. Protein Microarrays
    6. Others
  2. Next-Generation Gynecological Cancer Diagnostics Market, By Cancer Type 2022-2034 (USD MILLION/ Units)
    1. Breast
    2. Lung
    3. Colorectal
    4. Prostate
    5. Cervical
    6. Others
  3. Next-Generation Gynecological Cancer Diagnostics Market, By Function 2022-2034 (USD MILLION/ Units)
    1. Cancer Screening
    2. Therapeutic Monitoring
    3. Risk Analysis
  4. Regional Next-Generation Gynecological Cancer Diagnostics Market
    1. North America
      1. North America Next-Generation Gynecological Cancer Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
      2. North America Next-Generation Gynecological Cancer Diagnostics Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Breast
        2. Lung
        3. Colorectal
        4. Prostate
        5. Cervical
        6. Others
      3. North America Next-Generation Gynecological Cancer Diagnostics Market By Function 2022-2034 (USD MILLION/ Units)
        1. Cancer Screening
        2. Therapeutic Monitoring
        3. Risk Analysis
      4. U.S.
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      5. Canada
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
    2. Europe
      1. Europe Next-Generation Gynecological Cancer Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
      2. Europe Next-Generation Gynecological Cancer Diagnostics Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Breast
        2. Lung
        3. Colorectal
        4. Prostate
        5. Cervical
        6. Others
      3. Europe Next-Generation Gynecological Cancer Diagnostics Market By Function 2022-2034 (USD MILLION/ Units)
        1. Cancer Screening
        2. Therapeutic Monitoring
        3. Risk Analysis
      4. U.K.
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      5. Germany
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      6. France
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      7. Spain
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      8. Italy
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      9. Russia
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      10. Nordic
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      11. Benelux
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      12. Rest of Europe
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
    3. APAC
      1. APAC Next-Generation Gynecological Cancer Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
      2. APAC Next-Generation Gynecological Cancer Diagnostics Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Breast
        2. Lung
        3. Colorectal
        4. Prostate
        5. Cervical
        6. Others
      3. APAC Next-Generation Gynecological Cancer Diagnostics Market By Function 2022-2034 (USD MILLION/ Units)
        1. Cancer Screening
        2. Therapeutic Monitoring
        3. Risk Analysis
      4. China
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      5. Korea
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      6. Japan
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      7. India
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      8. Australia
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      9. Taiwan
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      10. South East Asia
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      11. Rest of Asia-Pacific
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
    4. Middle East and Africa
      1. Middle East and Africa Next-Generation Gynecological Cancer Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
      2. Middle East and Africa Next-Generation Gynecological Cancer Diagnostics Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Breast
        2. Lung
        3. Colorectal
        4. Prostate
        5. Cervical
        6. Others
      3. Middle East and Africa Next-Generation Gynecological Cancer Diagnostics Market By Function 2022-2034 (USD MILLION/ Units)
        1. Cancer Screening
        2. Therapeutic Monitoring
        3. Risk Analysis
      4. UAE
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      5. Turkey
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      6. Saudi Arabia
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      7. South Africa
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      8. Egypt
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      9. Nigeria
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      10. Rest of MEA
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
    5. LATAM
      1. LATAM Next-Generation Gynecological Cancer Diagnostics Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
      2. LATAM Next-Generation Gynecological Cancer Diagnostics Market By Cancer Type 2022-2034 (USD MILLION/ Units)
        1. Breast
        2. Lung
        3. Colorectal
        4. Prostate
        5. Cervical
        6. Others
      3. LATAM Next-Generation Gynecological Cancer Diagnostics Market By Function 2022-2034 (USD MILLION/ Units)
        1. Cancer Screening
        2. Therapeutic Monitoring
        3. Risk Analysis
      4. Brazil
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      5. Mexico
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      6. Argentina
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      7. Chile
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      8. Colombia
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
      9. Rest of LATAM
        1. Next generation sequencing
        2. Polymerase chain reaction (PCR)
        3. DNA Microarrays
        4. Multiplexing
        5. Protein Microarrays
        6. Others
        7. Breast
        8. Lung
        9. Colorectal
        10. Prostate
        11. Cervical
        12. Others
        13. Cancer Screening
        14. Therapeutic Monitoring
        15. Risk Analysis
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.